

<b>Audit Review Table</b>				
Presbyterian Health Plan, Inc. (Org ID: 579, SubID: 4104, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)				
Measurement Year - 2018; Date & Timestamp - 6/13/2019 6:02:05 PM				
The Auditor lock has been applied to this submission.				
Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment
<b>Effectiveness of Care: Prevention and</b>				
<b>Adult BMI Assessment (aba)</b>		87.34%	R	Reportable
<b>Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (wcc)</b>				
<i>BMI Percentile</i>		68.37%	R	Reportable
<i>Counseling for Nutrition</i>		56.69%	R	Reportable
<i>Counseling for Physical Activity</i>		48.18%	R	Reportable
<b>Childhood Immunization Status (cis)</b>				
<i>DTaP</i>		73.24%	R	Reportable
<i>IPV</i>		84.91%	R	Reportable
<i>MMR</i>		85.64%	R	Reportable
<i>H1B</i>		82.97%	R	Reportable
<i>Hepatitis B</i>		85.64%	R	Reportable
<i>VZV</i>		84.91%	R	Reportable
<i>Pneumococcal Conjugate</i>		75.43%	R	Reportable
<i>Hepatitis A</i>		84.43%	R	Reportable
<i>Rotavirus</i>		73.48%	R	Reportable
<i>Influenza</i>		52.31%	R	Reportable
<i>Combination #2</i>		68.61%	R	Reportable
<i>Combination #3</i>		65.45%	R	Reportable
<i>Combination #4</i>		63.99%	R	Reportable
<i>Combination #5</i>		58.64%	R	Reportable
<i>Combination #6</i>		43.55%	R	Reportable
<i>Combination #7</i>		57.42%	R	Reportable
<i>Combination #8</i>		43.55%	R	Reportable
<i>Combination #9</i>		39.17%	R	Reportable
<i>Combination #10</i>		39.17%	R	Reportable
<b>Immunizations for Adolescents (ima)</b>				
<i>Meningococcal</i>		75.18%	R	Reportable
<i>Tdap</i>		83.21%	R	Reportable
<i>HPV</i>		35.52%	R	Reportable
<i>Combination #1</i>		72.75%	R	Reportable
<i>Combination #2</i>		32.85%	R	Reportable
<b>Lead Screening in Children (lsc)</b>		38.69%	R	Reportable
<b>Breast Cancer Screening (bcs)</b>		50.16%	R	Reportable
<b>Cervical Cancer Screening (ccs)</b>		55.61%	R	Reportable
<b>Chlamydia Screening in Women (chl)</b>				
<i>16-20 Years</i>		46.41%	R	Reportable
<i>21-24 Years</i>		56.60%	R	Reportable
<i>Total</i>		50.41%	R	Reportable
<b>Effectiveness of Care: Respiratory</b>				
<b>Appropriate Testing for Children with Pharyngitis (cwp)</b>	Y	79.51%	R	Reportable
<b>Use of Spirometry Testing in the Assessment and Diagnosis of COPD (spr)</b>		22.22%	R	Reportable
<b>Pharmacotherapy Management of COPD Exacerbation (pce)</b>	Y			
<i>Systemic Corticosteroid</i>		46.25%	R	Reportable
<i>Bronchodilator</i>		53.56%	R	Reportable
<b>Medication Management for People With Asthma (mma)</b>	Y			
<i>5-11 Years: Medication Compliance 50%</i>		55.86%	R	Reportable
<i>5-11 Years: Medication Compliance 75%</i>		34.07%	R	Reportable
<i>12-18 Years: Medication Compliance 50%</i>		55.13%	R	Reportable
<i>12-18 Years: Medication Compliance 75%</i>		27.91%	R	Reportable
<i>19-50 Years: Medication Compliance 50%</i>		67.45%	R	Reportable
<i>19-50 Years: Medication Compliance 75%</i>		44.36%	R	Reportable
<i>51-64 Years: Medication Compliance 50%</i>		71.88%	R	Reportable
<i>51-64 Years: Medication Compliance 75%</i>		54.46%	R	Reportable
<i>Total: Medication Compliance 50%</i>		60.73%	R	Reportable
<i>Total: Medication Compliance 75%</i>		37.31%	R	Reportable

<b>Asthma Medication Ratio (amr)</b>	Y			
5-11 Years		68.46%	R	Reportable
12-18 Years		56.45%	R	Reportable
19-50 Years		45.65%	R	Reportable
51-64 Years		50.49%	R	Reportable
Total		55.36%	R	Reportable
<b>Effectiveness of Care: Cardiovascular</b>				
<b>Controlling High Blood Pressure (cbp)</b>		56.20%	R	Reportable
<b>Persistence of Beta-Blocker Treatment After a Heart Attack (pbh)</b>	Y	70.11%	R	Reportable
<b>Statin Therapy for Patients With Cardiovascular Disease (spc)</b>	Y			
Received Statin Therapy: 21-75 Years (Male)		58.29%	R	Reportable
Statin Adherence 80%: 21-75 Years (Male)		65.20%	R	Reportable
Received Statin Therapy: 40-75 Years (Female)		53.98%	R	Reportable
Statin Adherence 80%: 40-75 Years (Female)		57.38%	R	Reportable
Received Statin Therapy: Total		56.60%	R	Reportable
Statin Adherence 80%: Total		62.27%	R	Reportable
<b>Effectiveness of Care: Diabetes</b>				
<b>Comprehensive Diabetes Care (cdc)</b>				
Hemoglobin A1c (HbA1c) Testing		84.85%	R	Reportable
HbA1c Poor Control (>9.0%)		46.72%	R	Reportable
HbA1c Control (<8.0%)		44.89%	R	Reportable
HbA1c Control (<7.0%)		31.63%	R	Reportable
Eye Exam (Retinal) Performed		54.01%	R	Reportable
Medical Attention for Nephropathy		85.40%	R	Reportable
Blood Pressure Control (<140/90 mm Hg)		63.69%	R	Reportable
<b>Statin Therapy for Patients With Diabetes (spd)</b>	Y			
Received Statin Therapy		42.00%	R	Reportable
Statin Adherence 80%		58.37%	R	Reportable
<b>Effectiveness of Care: Musculoskeletal</b>				
<b>Disease-Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (art)</b>	Y	67.06%	R	Reportable
<b>Effectiveness of Care: Behavioral</b>				
<b>Antidepressant Medication Management (amm)</b>	Y			
Effective Acute Phase Treatment		53.74%	R	Reportable
Effective Continuation Phase Treatment		36.40%	R	Reportable
<b>Follow-Up Care for Children Prescribed ADHD Medication (add)</b>	Y			
Initiation Phase		30.11%	R	Reportable
Continuation and Maintenance (C&M) Phase		37.50%	R	Reportable
<b>Follow-Up After Hospitalization for Mental Illness (fuh)</b>	Y			
6-17 years - 30-Day Follow-Up		54.24%	R	Reportable
6-17 years - 7-Day Follow-Up		35.52%	R	Reportable
18-64 years - 30-Day Follow-Up		37.67%	R	Reportable
18-64 years - 7-Day Follow-Up		24.33%	R	Reportable
65+ years - 30-Day Follow-Up		53.33%	NA	Small Denominator
65+ years - 7-Day Follow-Up		26.67%	NA	Small Denominator
Total - 30-Day Follow-Up		42.66%	R	Reportable
Total - 7-Day Follow-Up		27.64%	R	Reportable
<b>Follow-Up After Emergency Department Visit for Mental Illness (fum)</b>	Y			
6-17 years - 30-Day Follow-Up		75.14%	R	Reportable
6-17 years - 7-Day Follow-Up		61.87%	R	Reportable
18-64 years - 30-Day Follow-Up		54.69%	R	Reportable
18-64 years - 7-Day Follow-Up		42.05%	R	Reportable
65+ years - 30-Day Follow-Up		50.00%	NA	Small Denominator
65+ years - 7-Day Follow-Up		25.00%	NA	Small Denominator
Total - 30-Day Follow-Up		61.94%	R	Reportable
Total - 7-Day Follow-Up		48.90%	R	Reportable
<b>Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (fua)</b>	Y			
30-Day Follow-Up: 13-17 Years		13.97%	R	Reportable
7-Day Follow-Up: 13-17 Years		9.56%	R	Reportable
30-Day Follow-Up: 18+ Years		18.95%	R	Reportable
7-Day Follow-Up: 18+ Years		11.50%	R	Reportable
30-Day Follow-Up: Total		18.73%	R	Reportable
7-Day Follow-Up: Total		11.41%	R	Reportable

Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (ssd)	Y	80.76%	R	Reportable
Diabetes Monitoring for People With Diabetes and Schizophrenia (smd)		57.98%	R	Reportable
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (smc)		61.54%	NA	Small Denominator
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa)	Y	55.54%	R	Reportable
Metabolic Monitoring for Children and Adolescents on Antipsychotics (apm)	Y			
1-5 Years		11.76%	NA	Small Denominator
6-11 Years		33.69%	R	Reportable
12-17 Years		36.05%	R	Reportable
Total		34.93%	R	Reportable
<b>Effectiveness of Care: Medication</b>				
Annual Monitoring for Patients on Persistent Medications (mpm)	Y			
ACE Inhibitors or ARBs		84.33%	R	Reportable
Diuretics		85.60%	R	Reportable
Total		84.80%	R	Reportable
<b>Effectiveness of Care:</b>				
Non-Recommended Cervical Cancer Screening in Adolescent Females (ncs)		0.79%	R	Reportable
Appropriate Treatment for Children With URI (uri)	Y	91.49%	R	Reportable
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (aab)	Y	36.19%	R	Reportable
Use of Imaging Studies for Low Back Pain (lbp)		72.50%	R	Reportable
Use of Multiple Concurrent Antipsychotics in Children and Adolescents (apc)	Y			
1-5 Years		0.00%	NA	Small Denominator
6-11 Years		4.17%	R	Reportable
12-17 Years		3.52%	R	Reportable
Total		3.69%	R	Reportable
Use of Opioids at High Dosage (uod)	Y	4.23%	R	Reportable
Use of Opioids From Multiple Providers (uop)	Y			
Multiple Prescribers		20.44%	R	Reportable
Multiple Pharmacies		8.24%	R	Reportable
Multiple Prescribers and Multiple Pharmacies		3.57%	R	Reportable
Risk of Continued Opioid Use (cou)	Y			
18-64 years - >=15 Days covered		8.77%	R	Reportable
18-64 years - >=31 Days covered		3.65%	R	Reportable
65+ years - >=15 Days covered		32.86%	R	Reportable
65+ years - >=31 Days covered		15.71%	R	Reportable
Total - >=15 Days covered		8.89%	R	Reportable
Total - >=31 Days covered		3.71%	R	Reportable
<b>Access/Availability of Care</b>				
Adults' Access to Preventive/Ambulatory Health Services (aap)				
20-44 Years		76.46%	R	Reportable
45-64 Years		82.56%	R	Reportable
65+ Years		89.26%	R	Reportable
Total		78.82%	R	Reportable
Children and Adolescents' Access to Primary Care Practitioners (cap)				
12-24 Months		90.13%	R	Reportable
25 Months - 6 Years		79.34%	R	Reportable
7-11 Years		82.45%	R	Reportable
12-19 Years		79.33%	R	Reportable
Annual Dental Visit (adv)	Y			
2-3 Years		58.08%	R	Reportable
4-6 Years		76.82%	R	Reportable
7-10 Years		80.31%	R	Reportable
11-14 Years		75.69%	R	Reportable

15-18 Years		66.63%	R	Reportable
19-20 Years		45.35%	R	Reportable
Total		71.31%	R	Reportable
<b>Initiation and Engagement of AOD Abuse or Dependence Treatment (iet)</b>	Y			
Alcohol abuse or dependence: Initiation of AOD Treatment: 13-17 Years		33.55%	R	Reportable
Alcohol abuse or dependence: Engagement of AOD Treatment: 13-17 Years		5.81%	R	Reportable
Opioid abuse or dependence: Initiation of AOD Treatment: 13-17 Years		50.00%	NA	Small Denominator
Opioid abuse or dependence: Engagement of AOD Treatment: 13-17 Years		14.29%	NA	Small Denominator
Other drug abuse or dependence: Initiation of AOD Treatment: 13-17 Years		46.81%	R	Reportable
Other drug abuse or dependence: Engagement of AOD Treatment: 13-17 Years		13.19%	R	Reportable
Total: Initiation of AOD Treatment: 13-17 Years		41.58%	R	Reportable
Total: Engagement of AOD Treatment: 13-17 Years		11.75%	R	Reportable
Alcohol abuse or dependence: Initiation of AOD Treatment: 18+ Years		39.60%	R	Reportable
Alcohol abuse or dependence: Engagement of AOD Treatment: 18+ Years		13.80%	R	Reportable
Opioid abuse or dependence: Initiation of AOD Treatment: 18+ Years		55.65%	R	Reportable
Opioid abuse or dependence: Engagement of AOD Treatment: 18+ Years		29.01%	R	Reportable
Other drug abuse or dependence: Initiation of AOD Treatment: 18+ Years		39.96%	R	Reportable
Other drug abuse or dependence: Engagement of AOD Treatment: 18+ Years		11.95%	R	Reportable
Total: Initiation of AOD Treatment: 18+ Years		42.45%	R	Reportable
Total: Engagement of AOD Treatment: 18+ Years		16.64%	R	Reportable
Alcohol abuse or dependence: Initiation of AOD Treatment: Total		39.32%	R	Reportable
Alcohol abuse or dependence: Engagement of AOD Treatment: Total		13.41%	R	Reportable
Opioid abuse or dependence: Initiation of AOD Treatment: Total		55.60%	R	Reportable
Opioid abuse or dependence: Engagement of AOD Treatment: Total		28.89%	R	Reportable
Other drug abuse or dependence: Initiation of AOD Treatment: Total		40.88%	R	Reportable
Other drug abuse or dependence: Engagement of AOD Treatment: Total		12.11%	R	Reportable
Total: Initiation of AOD Treatment: Total		42.39%	R	Reportable
Total: Engagement of AOD Treatment: Total		16.27%	R	Reportable
<b>Prenatal and Postpartum Care (ppc)</b>				
Timeliness of Prenatal Care		73.62%	R	Reportable
Postpartum Care		62.81%	R	Reportable
<b>Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (app)</b>	Y			
1-5 Years		54.55%	NA	Small Denominator
6-11 Years		69.68%	R	Reportable
12-17 Years		59.36%	R	Reportable
Total		62.40%	R	Reportable
<b>Utilization</b>				
<b>Well-Child Visits in the First 15 Months of Life (w15)</b>				
0 Visits		9.10%	R	Reportable
1 Visit		3.33%	R	Reportable
2 Visits		3.58%	R	Reportable
3 Visits		4.75%	R	Reportable
4 Visits		7.52%	R	Reportable
5 Visits		13.42%	R	Reportable
6+ Visits		58.30%	R	Reportable
<b>Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34)</b>		54.60%	R	Reportable
<b>Adolescent Well-Care Visits (awc)</b>		33.54%	R	Reportable
<b>Frequency of Selected Procedures (fsp)</b>			R	Reportable
<b>Ambulatory Care: Total (amba)</b>			R	Reportable

<b>Ambulatory Care: Dual Eligibles (ambb)</b>			R	Reportable
<b>Ambulatory Care: Disabled (ambc)</b>			R	Reportable
<b>Ambulatory Care: Other (ambd)</b>			R	Reportable
<b>Inpatient Utilization--General Hospital/Acute Care: Total (ipua)</b>			R	Reportable
<b>Inpatient Utilization--General Hospital/Acute Care: Dual Eligibles (ipub)</b>			R	Reportable
<b>Inpatient Utilization--General Hospital/Acute Care: Disabled (ipuc)</b>			R	Reportable
<b>Inpatient Utilization--General Hospital/Acute Care: Other (ipud)</b>			R	Reportable
<b>Identification of Alcohol and Other Drug Services: Total (iada)</b>	Y		R	Reportable
<b>Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)</b>	Y		R	Reportable
<b>Identification of Alcohol and Other Drug Services: Disabled (iadc)</b>	Y		R	Reportable
<b>Identification of Alcohol and Other Drug Services: Other (iadd)</b>	Y		R	Reportable
<b>Mental Health Utilization: Total (mpta)</b>	Y		R	Reportable
<b>Mental Health Utilization: Dual Eligibles (mptb)</b>	Y		R	Reportable
<b>Mental Health Utilization: Disabled (mptc)</b>	Y		R	Reportable
<b>Mental Health Utilization: Other (mptd)</b>	Y		R	Reportable
<b>Antibiotic Utilization: Total (abxa)</b>	Y		R	Reportable
<b>Antibiotic Utilization: Dual Eligibles (abxb)</b>	Y		R	Reportable
<b>Antibiotic Utilization: Disabled (abxc)</b>	Y		R	Reportable
<b>Antibiotic Utilization: Other (abxd)</b>	Y		R	Reportable
<b>Risk Adjusted Utilization</b>				
<b>Plan All-Cause Readmissions (pcr)</b>			R	Reportable
<b>Health Plan Descriptive</b>				
<b>Board Certification (bcr)</b>			UN	Unaudited
<b>Enrollment by Product Line: Total (enpa)</b>			R	Reportable
<b>Enrollment by Product Line: Dual Eligibles (enpb)</b>			R	Reportable
<b>Enrollment by Product Line: Disabled (enpc)</b>			R	Reportable
<b>Enrollment by Product Line: Other (enpd)</b>			R	Reportable
<b>Enrollment by State (ebs)</b>			R	Reportable
<b>Language Diversity of Membership (ldm)</b>			R	Reportable
<b>Race/Ethnicity Diversity of Membership (rdm)</b>			R	Reportable
<b>Total Membership (t1m)</b>			R	Reportable
<b>Measures Collected using Electronic</b>				
<b>Depression Screening and Follow-Up for Adolescents and Adults (dsf)</b>				
<i>Depression Screening: Total Total</i>			NR	Not Reported
<i>Follow-up on Positive Screen: Total Total</i>			NR	Not Reported
<b>Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (dms)</b>				
<i>Utilization of PHQ-9 - Time period 1: Total Total</i>			NR	Not Reported
<i>Utilization of PHQ-9 - Time period 2: Total Total</i>			NR	Not Reported
<i>Utilization of PHQ-9 - Time period 3: Total Total</i>			NR	Not Reported
<i>Utilization of PHQ-9 - Total: Total Total</i>			NR	Not Reported
<b>Depression and Remission or Response for Adolescents and Adults (drr)</b>				
<i>Follow-up PHQ-9: Total Total</i>			NR	Not Reported
<i>Depression Remission: Total Total</i>			NR	Not Reported
<i>Depression Response: Total Total</i>			NR	Not Reported
<b>Unhealthy Alcohol Use Screening and Follow-Up (asf)</b>				
<i>Alcohol Use Screening: Total Total</i>			NR	Not Reported
<i>Counseling or Other Follow-up Postive Screen: Total Total</i>			NR	Not Reported
<b>Adult Immunization Status (ais)</b>				
<i>Influenza: Total</i>			NR	Not Reported
<i>Td or Tdap: Total</i>			NR	Not Reported
<i>Zoster: Total</i>			NR	Not Reported
<i>Composite: Total</i>			NR	Not Reported
<b>Prenatal Immunization Status (prs)</b>				
<i>Influenza: Total</i>			NR	Not Reported
<i>Td or Tdap: Total</i>			NR	Not Reported

<i>Combination: Total</i>			NR	Not Reported
---------------------------	--	--	----	--------------